Skip to main content

Janssen promotes Maria Walsh to Business Unit Director, Oncology & Haematology, Cell & Gene Therapy and Pulmonary Hypertension for Janssen UK

Written by: Editor
Published on: 26 Jul 2022

JanssenHIGH WYCOMBE, UK, 26 JULY 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted to announce the appointment of Maria Walsh as Business Unit Director, Oncology & Haematology, Cell & Gene Therapy and Pulmonary Hypertension for Janssen UK, effective July 2022. Maria, who joined Janssen in May 2020, will transition from her current role as Commercial Lead in Haematology to her new role and join the Janssen UK leadership team.

Gaëtan Leblay, Managing Director, Janssen UK and Ireland, comments, “Maria is not only an experienced leader in Oncology, she is also a strategic thinker with an empathic and thoughtful management style. This is something she has previously drawn upon to navigate her team through complex and uncertain times with outstanding results. On behalf of the Janssen UK leadership team, I would like to extend a warm welcome to Maria Walsh and wish her every success in her new role”.

Before joining Janssen UK, Maria worked in marketing, sales, medical and market access roles at all stages of the product lifecycle, establishing deep expertise across multiple disciplines.

“I am thrilled to start my new role as Business Unit Director”, said Maria Walsh. “Over the last two years, I have proudly witnessed first-hand the hard work and dedication shown by the Janssen team as they successfully collaborate to deliver excellent outcomes. I look forward to leading the Oncology, Haematology, Cell & Gene Therapy and Pulmonary Hypertension franchises for Janssen UK, guided by our Credo to continue our longstanding commitment to the patients we serve and our employees.”